Skip to main content

Table 1 Clinical characteristics of study population

From: Intracellular lactate signaling cascade in atrial remodeling of mitral valvular patients with atrial fibrillation

Parameters

SR

PaAF

PeAF

Sex, M/F (n)

15/15

15/15

15/15

Age (years)

48.4±11.2

49.1.±10.1

48.7±10.8

Body mass index (kg/m 2 )

23.2±2.8

22.9±2.4

22.2±3.1

Heart rate (beats/min)

74±9

77±11

78±15

Mean artery pressure (mm Hg)

84.6±7.2

86.6±9.4

83.2±10.2

C-reactive protein (mg/L)

2.86±1.02

4.32±0.94*

5.04±1.21* , **

Duration of valvular disease (years)

4.9±4.8

6.9±5.7

12.5±7.2* , **

NYHA class I/II/III/IV (n)

4/9/14/3

3/7/15/5

2/4/17/7

Echocardiographic parameters

   

LVDd (mm)

48.6±7.4

50.4±6.8

49.2±8.1

LVDs (mm)

31.8±4.7

32.3±5.2

31.1±4.9

EF (%)

63.6±3.9

62.8±4.4

63.4±4.1

LAD (mm)

41.7±6.4

52.4±8.2*

59.9±9.4* , **

RAD (mm)

37.7±4.1

42.5±4.6*

46.3±5.7* , **

PASP (mm Hg)

34.2±7.7

44.1±11.3*

51.2±14.9* , **

Left atrial thrombus (n)

0

3

8* , **

Preoperative length of stay (days)

9.6±4.2

12.2±5.6*

15.8±6.8* , **

Cause of mitral valve disease (n)

   

Rheumatic/degenerative

22/8

24/6

28/2* , **

Preoperative drug (n)

   

Digitalis

30

30

30

Calcium-channel blocker

7

5

8

Beta-blocker

3

4

6

ACE-I

5

7

10

  1. Values are presented as mean±SD or number of patients.
  2. ACE-I angiotensin-converting enzyme inhibitor, EF ejection fraction, LAD left atrial diameter, LVDd left ventricular end-diastolic diameter, LVDs left ventricular end-systolic diameter, NYHA New York Heart Association, PASP pulmonary artery systolic pressure, RAD right atrial diameter.
  3. * p<0.05, reference group is the SR group.
  4. ** p<0.05, reference group is the PaAF group.